Literature DB >> 19693638

Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.

Marianna Argentou1, Dina G Tiniakos, Menelaos Karanikolas, Maria Melachrinou, Maria G Makri, Christos Kittas, Fotis Kalfarentzos.   

Abstract

BACKGROUND: Leptin, adiponectin, and resistin are adipokines linked to the development of insulin resistance, which plays a central role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). We aimed to define adipokine serum levels in severely obese patients undergoing bariatric surgery and to correlate these with anthropometric and metabolic variables, liver function tests, and histopathological parameters of NAFLD and nonalcoholic steatohepatitis (NASH).
METHODS: Surgical liver biopsies were obtained from 50 bariatric patients with no history of liver disease or significant alcohol consumption. Serum leptin, adiponectin, and resistin levels were measured, and histology was assessed using Brunt's and Kleiner's scoring systems.
RESULTS: Waist/hip ratio was significantly higher in men (p = 0.0001), and leptin (p = 0.036) and adiponectin (p = 0.0001) serum levels were higher in women. Forty-one of 50 patients (82%) had histological NAFLD, including 10 (20%) with NASH. Nine patients (18%) had normal liver histology (obese control subgroup). In NAFLD patients, serum adiponectin was negatively correlated with activity grade and fibrosis stage, resistin was negatively correlated with steatosis grade (p = 0.033), while leptin was not related to histology. Leptin/adiponectin ratio showed positive association with stage (p = 0.044). In the subgroup of NASH patients, adiponectin was negatively correlated only with stage (p = 0.01), while there was no correlation between leptin, resistin, or leptin/adiponectin and histology.
CONCLUSIONS: Serum adiponectin and resistin levels are related to liver histology in bariatric patients and may be indicative of the histological severity of NAFLD and the extent of hepatic steatosis, respectively. Serum leptin levels are not informative of underlying liver histology in severely obese patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693638     DOI: 10.1007/s11695-009-9912-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  58 in total

1.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

2.  Serum resistin and hepatic fat content in nondiabetic individuals.

Authors:  Gianluca Perseghin; Guido Lattuada; Francesco De Cobelli; Georgia Ntali; Antonio Esposito; Agata Burska; Elena Belloni; Tamara Canu; Francesca Ragogna; Paola Scifo; Alessandro Del Maschio; Livio Luzi
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

Review 3.  The evolving role of leptin and adiponectin in chronic liver diseases.

Authors:  Emmanuel Tsochatzis; George V Papatheodoridis; Athanasios J Archimandritis
Journal:  Am J Gastroenterol       Date:  2006-09-04       Impact factor: 10.864

4.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.

Authors:  Masato Yoneda; Tomoyuki Iwasaki; Koji Fujita; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Shiro Maeyama; Koichiro Wada; Satoru Saito; Yasuo Terauchi; Atsushi Nakajima
Journal:  Alcohol Clin Exp Res       Date:  2007-01       Impact factor: 3.455

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

8.  Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.

Authors:  Michael Charlton; Paul Angulo; Naga Chalasani; Ralph Merriman; Kimberly Viker; Phunchai Charatcharoenwitthaya; Schuyler Sanderson; Samer Gawrieh; Anuradha Krishnan; Keith Lindor
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease.

Authors:  Rocio Aller; Daniel A de Luis; Luis Fernandez; Fernando Calle; Benito Velayos; Jose Luis Olcoz; Olatz Izaola; Manuel Gonzalez Sagrado; Rosa Conde; Jose Manuel Gonzalez
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 10.  Obesity and nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  Nutr Rev       Date:  2007-06       Impact factor: 7.110

View more
  14 in total

1.  Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease.

Authors:  Valentina Medici; Mohamed R Ali; Suk Seo; Christopher A Aoki; Lorenzo Rossaro; Kyoungmi Kim; Will D Fuller; Tamas J Vidovszky; William Smith; Joy X Jiang; Kalyani Maganti; Peter J Havel; Amit Kamboj; Rajendra Ramsamooj; Natalie J Török
Journal:  Obesity (Silver Spring)       Date:  2010-05-06       Impact factor: 5.002

2.  Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients.

Authors:  Rafael Bergesch D'Incao; Cristiane Valle Tovo; Vanessa Suñé Mattevi; Diego Olschowsky Borges; Jane Maria Ulbrich; Gabriela Perdomo Coral; Mauricio Jacques Ramos; Nelson Guardiola Meinhardt
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

3.  Leptin induces an inflammatory phenotype in lean Wistar rats.

Authors:  Monique Allman; Mathew Wallace; Latausha Gaskin; Chantal A Rivera
Journal:  Mediators Inflamm       Date:  2010-01-26       Impact factor: 4.711

Review 4.  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Stergios A Polyzos; Konstantinos N Aronis; Jannis Kountouras; Dimitrios D Raptis; Maria F Vasiloglou; Christos S Mantzoros
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

Review 5.  Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Authors:  J K Dowman; J W Tomlinson; P N Newsome
Journal:  Aliment Pharmacol Ther       Date:  2010-12-29       Impact factor: 8.171

Review 6.  Diagnosis and evaluation of nonalcoholic fatty liver disease.

Authors:  Mikako Obika; Hirofumi Noguchi
Journal:  Exp Diabetes Res       Date:  2011-10-27

Review 7.  Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions.

Authors:  Timon E Adolph; Christoph Grander; Felix Grabherr; Herbert Tilg
Journal:  Int J Mol Sci       Date:  2017-07-29       Impact factor: 5.923

Review 8.  Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.

Authors:  Hyun-Seuk Moon; Maria Dalamaga; Sang-Yong Kim; Stergios A Polyzos; Ole-Petter Hamnvik; Faidon Magkos; Jason Paruthi; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2013-03-08       Impact factor: 19.871

Review 9.  Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH).

Authors:  Akinobu Takaki; Daisuke Kawai; Kazuhide Yamamoto
Journal:  Int J Mol Sci       Date:  2013-10-15       Impact factor: 5.923

Review 10.  Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Chrysoula Boutari; Nikolaos Perakakis; Christos Socrates Mantzoros
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.